{
    "clinical_study": {
        "@rank": "92342", 
        "arm_group": {
            "arm_group_label": "Patients with PAD"
        }, 
        "brief_summary": {
            "textblock": "In this prospective study, a newly developed self-expanding nitinol stent is evaluated for\n      the treatment of atherosclerotic lesions in the superficial femoral artery."
        }, 
        "brief_title": "Endovascular Treatment of Atherosclerotic Lesions in the SFA Using the Sinus-superflex-635 Stent", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Atherosclerotic Heart Disease", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Heart Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient must sign informed consent prior to the index-procedure\n\n          -  Patient must be older than 18 years\n\n          -  Patient must be compliant with follow-up dates at 1 month and 12 months\n\n          -  Patients with intermittent claudication (Rutherford 2-3) and critical limb ischemia\n             (Rutherford 4-5)\n\n          -  Target lesion is located in the superficial femoral artery (minimal 1 cm from origin\n             of SFA and minimal 1 cm above the edge of the patella)\n\n          -  Reference vessel diameter \u22654.5 and \u22646.5 mm (visual estimate)\n\n          -  Patients with a TASC A, B or C lesion\n\n          -  Diameter stenosis of target lesion >50% or chronic occlusions\n\n          -  Inflow arteries are free of hemodynamically significant obstruction (i.e. \u226550%)\n\n          -  The popliteal artery (outflow) is free of hemodynamically significant obstruction\n             (i.e. \u226550%)\n\n          -  At least 1 patent below-the-knee vessel (anterior tibial artery, posterior tibial\n             artery or peroneal artery) till the ankle confirmed by baseline angiography\n\n        Exclusion Criteria:\n\n          -  Patients with Rutherford 1 and 6\n\n          -  Patiens with Serum creatinine > 2.0 mg/dL or renal dialysis\n\n          -  Patient takes esomeprazole or omeprazole\n\n          -  Patient is pregnant\n\n          -  Patient suffers from acute limb ischemia defined as any sudden decrease in limb\n             perfusion causing a potential threat to limb viability\n\n          -  Target lesion cannot be crossed with a guidewire\n\n          -  Target lesion is located in the popliteal artery\n\n          -  Patients with a nickel-titanium allergy\n\n          -  Patients with an aneurysm in the superficial femoral artery and popliteal artery\n\n          -  Patients with a TASC D lesion\n\n          -  Patients with a life expectancy <1 year\n\n          -  Patients with scheduled elective non-vascular procedures within 3 months after\n             index-procedure, vascular procedures are allowed within 3 months after\n             index-procedure if it is guaranteed that acetylic salicylic acid and clopidogrel\n             intake is not interrupted\n\n          -  Patients with previous bypass surgery in the SFA\n\n          -  Patients with intolerance to antithrombotic medication (acetylic salicylic acid,\n             clopidogrel, ticlopidine, glycoprotein IIb/IIIa inhibitors, direct thrombin\n             inhibitors, etc)\n\n          -  Patient has not been premedicated with acetylic salicylic acid (at least 80 mg/day) 2\n             hours before the index-procedure\n\n          -  Patient has not been premedicated with clopidogrel (600 mg/day) 2 hours before the\n             index-procedure"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients who suffer from intermittent claudication and critical limb ischemia (TASC A, B\n        and C lesions)."
            }
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01816854", 
            "org_study_id": "BM-HERO-07"
        }, 
        "intervention": {
            "arm_group_label": "Patients with PAD", 
            "intervention_name": "Stenting", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "SFA,", 
            "stent,", 
            "endovascular", 
            "Patient outcome"
        ], 
        "lastchanged_date": "May 13, 2014", 
        "location": {
            "contact": {
                "last_name": "Jeroen Hendriks, MD, PhD"
            }, 
            "facility": {
                "address": {
                    "city": "Antwerp", 
                    "country": "Belgium", 
                    "zip": "2650"
                }, 
                "name": "Antwerp University Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_groups": "1", 
        "official_title": "Endovascular Treatment of Atherosclerotic Lesions in the SFA Using the Sinus-superflex-635 Stent", 
        "overall_contact": {
            "email": "jeroen.hendriks@uza.be", 
            "last_name": "Jeroen Hendriks, MD, PhD", 
            "phone": "+32 3 821 30 00"
        }, 
        "overall_contact_backup": {
            "last_name": "Joris Coteur, MSc"
        }, 
        "overall_official": {
            "affiliation": "University Hospital, Antwerp", 
            "last_name": "Jeroen Hendriks, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Belgium: FAMHP", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Binary restenosis is defined as a re-obstruction \u2265 50% of the target lesion (peak systolic velocity ratio > 2.4).", 
            "measure": "Binary restenosis", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01816854"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Procedural success: combination of technical success, device success and absence of procedural complications.\nTechnical success: successful vascular access and completion of the endovascular procedure and immediate morphological success with less than 30% residual diameter reduction of the treated lesion on completion angiography.\nDevice success: exact deployment of the device according to the instructions for use as documented with suitable imaging modalities and in case of digital substraction angiography, in at least two different imaging projections.", 
                "measure": "Immediate procedural outcome (procedural, technical and device success)", 
                "safety_issue": "Yes", 
                "time_frame": "peri-procedural"
            }, 
            {
                "measure": "Distribution of Rutherford stages", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Defined as sustained upward shift of at least one category on the Rutherford classification without the need for repeated target lesion revascularization (TLR) in surviving patients.", 
                "measure": "Primary sustained clinical improvement", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Defined as sustained upward shift of at least one category on the Rutherford classification including the need for repeated TLR in surviving patients.", 
                "measure": "Secondary sustained clinical improvement at 12 months", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "post-procedural", 
                "measure": "Mortality", 
                "safety_issue": "Yes", 
                "time_frame": "30-day mortality"
            }, 
            {
                "measure": "Mortality", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Repeated target lesion revascularization (TLR) rate", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Repeated target extremity revascularization (TER) rate", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Amputation rate", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Rate of patient clopidogrel resistance", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }
        ], 
        "source": "be Medical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "be Medical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "12 Months", 
        "verification_date": "May 2014"
    }
}